基于4-基基酸修饰的pH响应性半IPN纳米颗粒,用于有针对性和受控地释放化疗药物
Mohammed Abul Hasnat1, Raymond Shikuku1, Makoto Takafuji2
1Bio-NanoMaterials Research Laboratory, Department of Applied Chemistry and Chemical Engineering, Faculty of Engineering and Technology, University of Dhaka, Dhaka 1000, Bangladesh.
ACS omega
|February 23, 2026
概括
新的基托桑纳米颗粒 (NP) 与4-基基酸 (PBA) 有效地向瘤. 这些基于PBA修饰的基托 (PBA-CS) 半透聚合物网络 (半IPN) 的NP显示了化学疗法的高药载荷和受控释放.
科学领域:
- 生物材料科学 生物材料科学
- 纳米技术 纳米技术
- 聚合物化学 聚合物化学
背景情况:
- 用4 - 碳氧 - 酸 (PBA) 修改的基托桑纳米颗粒 (NPs) 是癌症治疗的前景.
- PBA结合增强了纳米载体的活跃向和药物载荷能力.
研究的目的:
- 开发基于PBA修饰的基托 (PBA-CS) 半相互透的聚合物网络 (半IPN) 纳米粒子.
- 评估它们作为多克索鲁比 (Dox) 化疗纳米载体的潜力.
主要方法:
- 通过自由基聚合合成的PBA-CS-PVIm和PBA-CS-PMAA半IPNNP.
- 使用ATR-FTIR,TEM和TGA进行了NPs的特征.
- 在不同的pH值下评估了Dox的负载能力,封装效率和体外释放动力学.
- 在HeLa和Vero细胞系中评估了细胞毒性.
主要成果:
- 获得了平均直径为33.86nm (PBA-CS-PVIm) 和31.28nm (PBA-CS-PMAA) 的球形NP.
- 高正泽塔电位 (+41.1 mV和+35.9 mV) 表示稳定性良好.
- 在pH 5.5.5下,PBA-CS-PVIm NP表现出较高的Dox负载 (180 ± 6 mg/g) 和封装 (66 ± 3%).
- 在120小时内持续释放Dox,其中78%来自PBA-CS-PMAA和65%来自PBA-CS-PVIm.
- 载有Dox的NP在HeLa细胞中表现出显著的细胞毒性,在Vero细胞中表现出极好的生物相容性.
结论:
- 基于PBA-CS的半IPNNP是有效的纳米载体,可以传递多克索鲁比.
- 这些NP表明pH响应药物释放和向细胞毒性.
- 这些发现突显了PBA-CS半IPNNP在癌症化疗中的潜力.
相关概念视频
Site-Targeted Drug Delivery Systems: Polymeric Carriers
39
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
39
Modified-Release Drug Delivery Systems: Site-Targeted
33
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
33
Modified-Release Drug Delivery Systems: Stimuli-Activated
35
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
35
Modified-Release Drug Delivery Systems: Classification
47
Modified-release drug delivery systems improve drug efficacy and minimize side effects by controlling the rate and location of drug release. These systems fall into three categories: rate-programmed, stimuli-activated, and site-targeted.Rate-programmed systems release drugs at a predetermined rate, maintaining consistent therapeutic levels and reducing fluctuations that could lead to toxicity or subtherapeutic effects. These systems use polymeric matrices, reservoir-based designs, or osmotic...
47
Modified-Release Drug Delivery Systems: Rate-Programmed II
44
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
44


